Sanofi stock edges higher as Deutsche Bank reiterates Buy rating

Published on 09/14/2026 at 14:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Sanofi stock closed at USD 42.77 on Nasdaq on September 11, 2026, modestly above its prior close while market data put its value above USD 100 billion. Deutsche Bank Research reiterated a Buy rating with a EUR 95 price target, highlighting upside potential versus the current Paris price.

Fotorealistisches TV-Studio mit Kameras, Lichtern und Nachrichtendesk in Paris — Vivendi SE (FR0000127771) betreibt Medienstudios; dieses Bild zeigt ein realistisches TV-Studio mit Kameratechnik und Regie, Illustration mit AI erstellt.

Sanofi S.A. (ISIN FR0000127771) stock closed at USD 42.77 on Nasdaq on September 11, 2026, up 0.12% from the prior close of USD 42.72 and leaving the healthcare group valued at a little over USD 100 billion in recent market data. As of early September 2026, Sanofi’s trailing 12-month revenue stood at USD 55.9 billion with an 8.1% net profit margin, underlining the earnings power behind the share price.

Deutsche Bank sticks to Buy with EUR 95 target

According to finanzen.ch on September 14, 2026, Deutsche Bank Research has reaffirmed its Buy rating on Sanofi with a price target of EUR 95, compared with a contemporaneous Euronext Paris price of about EUR 74.52, implying roughly 27.5% upside from the spot level. The same analyst overview notes that the current price used in the Deutsche Bank calculation was EUR 74.50, underscoring that the valuation gap is based on up-to-date trading data on the Paris listing.

The Deutsche Bank stance comes against a backdrop of more cautious views from other houses. As MarketScreener reported on September 14, 2026, RBC Capital Markets has Sanofi at Neutral, and Barclays also maintains a Neutral rating, pointing to limited short-term catalysts despite ongoing management efforts. For investors, the divergence between a Buy call with double-digit implied upside and more neutral stances is a key element of the current debate around Sanofi stock.

Recent revenue, earnings and valuation in focus

A recent comparison of Sanofi with Novo Nordisk from AAII on September 1, 2026, highlights that Sanofi generated trailing 12-month revenue of USD 55.9 billion with an 8.1% net profit margin, compared with analysts’ expectations for adjusted earnings of USD 4.986 per share for the current fiscal year. The same analysis notes that Sanofi’s dividend yield stood at 5.5%, giving the stock an income angle alongside capital appreciation potential. In that period, Sanofi’s stock was down 8.2% year to date and 10.33% over the past year, showing that the solid earnings base has not yet translated into strong share performance.

Per Nasdaq-linked data summarized by Yahoo Finance, Sanofi’s US ADR (ticker SNY) reported Q2 fiscal 2026 revenue of USD 11.6 billion and earnings of USD 343 million, corresponding to a profit margin of 2.96%. These interim figures are the most recent quarterly data and underpin the trailing revenue profile used in the AAII comparison. The quarterly margin is lower than the trailing 12-month net margin of 8.1% cited by AAII, suggesting that recent quarters have been softer than the longer-term average and helping to explain why the stock trades on a price-earnings ratio of about 12.0 rather than a richer multiple.

The AAII overview points out that as of September 1, 2026, Sanofi carried a market capitalization of USD 106.7 billion and was down 8.2% in 2026, which compares with a 12.73% decline in market cap for 2026 in the time series compiled by CompaniesMarketCap. On September 12, 2026, CompaniesMarketCap reported Sanofi’s market cap at USD 102.48 billion, slightly below a USD 104.30 billion figure noted by Nasdaq for the same day, illustrating normal variation in third-party estimates but confirming that the company currently sits just above the USD 100 billion mark.

Risk factors and upcoming earnings date

Analyst commentary collated by MarketScreener emphasizes that RBC Capital Markets initiated coverage with a Sector Perform stance and highlighted limited near-term catalysts despite a management turnaround. Barclays also keeps a Neutral rating, reinforcing the perception that, while Sanofi is financially solid, the pipeline and strategic moves may need more time to convince more cautious houses. This contrast between a bullish EUR 95 target from Deutsche Bank and Neutral ratings from RBC and Barclays is an important risk consideration for holders of Sanofi stock: if pipeline milestones or margin improvements disappoint, the upside implied by the Buy thesis could narrow.

From an events perspective, the next key checkpoint is the earnings date listed for Sanofi’s ADR. According to Yahoo Finance, the next earnings date for Sanofi is scheduled for October 30, 2026, giving investors a clear timeframe for when updated revenue, earnings and guidance figures will be released. With Q2 fiscal 2026 already showing revenue of USD 11.6 billion and earnings of USD 343 million, the upcoming report will indicate whether margins are recovering toward the trailing 8.1% net level or remain compressed.

Sanofi stock price and market position

On the US market, Sanofi’s ADR (SNY) closed at USD 42.77 on Nasdaq on September 11, 2026, with an after-hours indication of USD 42.75 later that day, based on data from Yahoo Finance. The prior close was USD 42.72, so the move represented a modest 0.12% daily gain, leaving the ADR some distance below the EUR 74.63 spot price quoted for the Paris listing at 10:46 on September 14, 2026 in the MarketScreener real-time overview. With a market capitalization around USD 102.48 billion as of September 12, 2026, Sanofi currently ranks in the low 200s globally by value, and AAII places the company in the 97th percentile of all stocks by market cap as of September 1, 2026.